Precision BioSciences, a genome-editing company, has brought in an investment banker who helped with its IPO to run financial strategy and investor relations.
Nicholas Riddle joins the bioscience company from JPMorgan where he spent four years working in the healthcare investment banking group.
Earlier this year, he was one of the advisers who helped Precision raise $145 mn during its IPO on Nasdaq. JPMorgan worked as joint bookrunner on the offering alongside Goldman Sachs, Jefferies and Barclays.
Prior to joining JPMorgan, Riddle spent two years as an equity analyst at York Capital Management in its London offices. Previously, he spent eight years studying at the University of Cambridge where he earned a PhD in neurophysiology.
‘Nick played an important role in our successful IPO earlier this year as a financial adviser to Precision, and we expect his combination of extensive capital markets and corporate finance experience together with his medical scientific background will be a significant asset as we continue to grow as a public company,’ says Matt Kane, CEO and co-founder of Precision, in a company statement.
‘Having worked closely with Precision in an advisory capacity, I am thrilled to now be part of the team,’ adds Riddle in the statement.
Precision, based in North Carolina, US, has developed a proprietary genome-editing platform. The firm focuses on three areas: treating cancer, curing genetic diseases and improving food-production systems.
